Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph-negative acute lymphoblastic leukemia relapsed post CD19 CART therapy.

Si-Man HuangChao-Ling WanHan-Yu CaoYan-Yan LiChong-Sheng QianHai-Xia ZhouMing-Zhu XuXiao-Hui HuLan DaiHai-Ping DaiSheng-Li Xue

Published in: Clinical case reports (2023)

There are no reports of application of inotuzumab ozogamicin (InO) for the treatment of MRD in r/r B-ALL. We firstly report the efficacy of InO for a patient experienced morphological relapse after HSCT and molecular relapse after CART therapy.

Keyphrases

acute lymphoblastic leukemia
allogeneic hematopoietic stem cell transplantation
free survival
stem cells
emergency department
case report
cell therapy
hodgkin lymphoma
combination therapy